ORIGINAL ARTICLE |
|
Year : 2019 | Volume
: 6
| Issue : 3 | Page : 124-127 |
|
Netrin-1 expression in breast cancer
Shyr-Ming Sheen-Chen1, Ching-Hua Tsai2, Yueh-Wei Liu2, Chao-Cheng Huang3
1 Department of Surgery, Taipei Tzu Chi Hospital, Taipei, Taiwan 2 Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, Taiwan 3 Department of Pathology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, Taiwan
Correspondence Address:
Dr. Shyr-Ming Sheen-Chen Department of Surgery, Taipei Tzu Chi Hospital, No. 289, Jianguo Road, Xindian District, New Taipei City 23142 Taiwan
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/JCRP.JCRP_8_19
|
|
Background: Breast cancer is a collection of molecularly and clinically distinct neoplastic disease. Recent research has shown that the gene expression in breast cancer can be useful when designing an optimal treatment plan and may also provide with prognostic information. The development of tissue microarrays (TMAs) has allowed for rapid immunohistochemical analysis of thousands of tissue samples in parallel with minimal damage to the original blocks. The aim of this study was to use TMAs to analyze the netrin-1 (NTN 1) status in patients with breast cancer with the hope of elucidating the possible relationship between NTN 1 expressions and breast cancer. Materials and Methods: Archival tissue specimens from 106 patients with primary invasive breast cancer were analyzed for NTN 1 expression using immunohistochemical staining with TMAs. Results were compared to clinicopathological data using multivariate analysis. Results: Tumor-node-metastasis stage was significantly related to the overall 5-year survival rate; however, NTN 1 expression was not significantly associated with overall 5-year survival. Conclusion: Immunohistochemical staining with TMAs was convenient and feasible to analyze the expression of NTN 1, in patients with breast cancer. Our preliminary results showed that NTN 1 expression had no significant prognostic value in breast cancer.
|
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|